GFP Reporter Cell Line - PC-9

Lung cancer is one of the most common malignancies with the highest morbidity and mortality. The 5-year survival rate of lung cancer patients after diagnosis is only 19%, which highlights the huge challenges in lung cancer treatment. These findings highlight the urgent need to develop more effective treatment strategies to improve the prognosis of lung cancer patients. The researchers used the GFP Reporter Cell Line - PC-9 cell line to explore the role of YAP1 in osimertinib resistance. They used a novel inhibitor, CA3, to inhibit YAP1 and combined it with osimertinib. Through this method, the researchers observed that cell proliferation and metastasis were significantly inhibited, while apoptosis and autophagy were induced, delaying the emergence of osimertinib resistance. The researchers also found that CA3 combined with osimertinib partially achieved its anti-metastasis and tumor apoptosis-promoting effects through the autophagy pathway. In terms of mechanism, the researchers elucidated the process by which YAP1 and YY1 cooperate to transcriptionally inhibit DUSP1, leading to dephosphorylation of the EGFR/MEK/ERK pathway and phosphorylation of YAP1. These findings provide new ideas and potential treatment strategies for overcoming osimertinib resistance.

Figure 1. The researchers used the GFP Reporter Cell Line - PC-9 cell line to study the effects of YAP1 on autophagy, apoptosis, and metastasis. They observed the effects of CA3 and osimertinib alone or in combination on cells by electron microscopy, western blotting, immunofluorescence, and flow cytometry. The researchers also used chloroquine pretreatment to explore the role of autophagy in these processes and analyzed the effects of drug treatment on cell metastasis ability by Transwell assay. (Ning Y, et al., 2023)